In advanced NSCLC without targetable molecular alterations, validated first-line treatment is now based on monotherapy or combination therapy with immune checkpoint inhibitors (ICIs) that target programmed death 1 receptor (PD-1), its ligand (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [5,6,7]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.